Salvage Therapy with Mitomycin and Ifosfamide in Patients with Gemcitabine-Resistant Metastatic Pancreatic Cancer: A Phase II Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Salvage Therapy with Mitomycin and Ifosfamide in Patients with Gemcitabine-Resistant Metastatic Pancreatic Cancer: A Phase II Trial

Published:2011 Issue:2 Volume:57 Page:156-161
ISSN:1421-9794
Container-title:Chemotherapy
language:en
Short-container-title:Chemotherapy

Author:

Cereda Stefano,Reni Michele,Rognone Alessia,Fugazza Clara,Ghidini Michele,Ceraulo Domenica,Brioschi Matteo,Nicoletti Roberto,Villa Eugenio

Publisher

S. Karger AG

Subject

Infectious Diseases,Pharmacology (medical),Drug Discovery,Pharmacology,Oncology,General Medicine

Reference48 articles.

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

2. Efficacy of Gemcitabine for Locally Advanced Pancreatic Cancer: Comparison with 5-Fluorouracil-Based Chemoradiotherapy

3. Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

5. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the therapeutic effect of mitomycin-loaded hydrogel in inhibiting tumor-cell proliferation and invasion in pancreatic cancer;Materials Express;2023-01-01

2. A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma;Journal of Pancreatic Cancer;2019-05

3. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?;OncoTargets and Therapy;2018-08

4. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?;Critical Reviews in Oncology/Hematology;2017-07

5. Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma;Cancer Chemotherapy and Pharmacology;2015-12-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3